Standing Committee for Clinical Affairs
EULAR Study Groups
Focus groups withing the sphere of musculoskeletal medicine may apply for EULAR endorsement and also support through the Standing Committee for Clinical Affairs.
- EUSTAR (EULAR Scleroderma Trials And Research) group
The EULAR Scleroderma Trials and Research (EUSTAR) group was founded in June 2004 as an ESCCA taskforce. A core feature of EUSTAR was the Minnimal Essential Data Set (MEDS): specific aims were to establish a core data set on as many SSc patients as possible in order to encourage further in-depth multicenter studies.
As of March 2010, over 8'500 patients are registered in MEDA from 90 centres in 5 continents.
Official website >> - EUVAS (European Vasculitis Study Group)
Aimed at encouraging multicentre clinical trials in vasculitis, this EU initiated multidisciplinary group is endorsed and partly supported by EULAR.
Official website >> - EULAR Systemic Lupus Erythematosus (SLE) Study Group
This is a study group that evolved from the EULAR Task Force on SLE that has published recommendations on the diagnosis and management of SLE, neuropsychiatric lupus and lupus nephritis, all published in the Ann Rheum Dis (available at the EULAR website). In addition, the task force has published recommendations on points to consider for conducting lupus clinical trials.
Read more >> - EULAR OA Trial Data Bank Study Group
Based on small to moderate effectiveness of the wide range of symptomatic treatments in OA, and the heterogeneity of OA patients, treatment guidelines for OA have stressed the need for research on clinical predictors of response to different treatments. EULAR endorses this inititative and will help increase the visibility towards all data-deliverers and all individuals interested in joining this study group.
Read more >> - EULAR Lupus Nephritis Trial Network Study Group
The mission of the Lupus Nephritis Trial Network (LNTN) is to improve outcomes for patients with lupus nephritis through: (1) the conduct of clinical trials designed to prevent chronic kidney disease and end-stage kidney failure, and (2) the development of clinical trial methodologies that improve and simplify the assessment of therapeutic agents.
Read more >>
